loading

Kazia Therapeutics Limited Adr Aktie (KZIA) Neueste Nachrichten

pulisher
Apr 15, 2025

SEC Form 424B3 filed by Kazia Therapeutics Limited - Quantisnow

Apr 15, 2025
pulisher
Mar 31, 2025

Kazia Therapeutics sells Cantrixil rights for $1 million - Investing.com India

Mar 31, 2025
pulisher
Mar 31, 2025

Kazia's Million-Dollar Deal: Cantrixil Cancer Drug IP Rights Sold as Development Path Shifts - Stock Titan

Mar 31, 2025
pulisher
Mar 13, 2025

Kazia Therapeutics shares annual report details By Investing.com - Investing.com South Africa

Mar 13, 2025
pulisher
Mar 13, 2025

Kazia Therapeutics shares annual report details - Investing.com

Mar 13, 2025
pulisher
Mar 12, 2025

Best upcoming stock splits and reverse splits 2024 - Investorsobserver

Mar 12, 2025
pulisher
Feb 20, 2025

Kazia Therapeutics and the Hebrew University of Jerusalem Receives a Grant from The Michael J. Fox Foundation to Evaluate the Therapeutic Potential of Paxalisib as a Treatment for Parkinson's Disease - BioSpace

Feb 20, 2025
pulisher
Feb 20, 2025

Kazia explores paxalisib for Parkinson's with MJFF grant - Investing.com

Feb 20, 2025
pulisher
Feb 20, 2025

Can This Brain-Penetrating Drug Breakthrough Transform Parkinson's Treatment? Major Foundation Thinks So - Stock Titan

Feb 20, 2025
pulisher
Feb 11, 2025

KZIA’s Stock Journey: What Investors Need to Know About Kazia Therapeutics Limited ADR’s Performance - The InvestChronicle

Feb 11, 2025
pulisher
Feb 10, 2025

Kazia Therapeutics Limited ADR (KZIA) Stock: Analyzing the Market Value - The News Heater

Feb 10, 2025
pulisher
Feb 10, 2025

SolarBank Corporation (SUUN) Stock: Evaluating the Market Performance - The News Heater

Feb 10, 2025
pulisher
Feb 10, 2025

Aditxt Inc (ADTX) Stock: A Look at the Analyst Recommendations - The News Heater

Feb 10, 2025
pulisher
Feb 08, 2025

Maxim Group Begins Coverage on Kazia Therapeutics (NASDAQ:KZIA) - Defense World

Feb 08, 2025
pulisher
Jan 30, 2025

10 Best ASX Stocks to Buy According to Hedge Funds - Insider Monkey

Jan 30, 2025
pulisher
Jan 30, 2025

Game-Changing Cancer Trial: Kazia's New Drug Combo Could Unmask Hidden Breast Cancer Cells - StockTitan

Jan 30, 2025
pulisher
Jan 27, 2025

Why Kazia Therapeutics (KZIA) Is Among the Best Australian Stocks to Buy Now? - Insider Monkey

Jan 27, 2025
pulisher
Jan 26, 2025

10 Best Australian Stocks to Buy Now - Insider Monkey

Jan 26, 2025
pulisher
Jan 14, 2025

Kazia Therapeutics Secures $2M Funding Through Direct Offering to Alumni Capital - StockTitan

Jan 14, 2025
pulisher
Jan 10, 2025

Kazia Therapeutics secures $2 million in direct offering - Investing.com India

Jan 10, 2025
pulisher
Jan 10, 2025

Kazia Therapeutics Secures $2M Funding Through Direct Offering at $1.50 Per ADS - StockTitan

Jan 10, 2025
pulisher
Dec 31, 2024

Why Is Brain Cancer-Focused Kazia Therapeutics Stock Trading Lower On Tuesday? - Yahoo Finance

Dec 31, 2024
pulisher
Dec 31, 2024

Kazia aligns with FDA on glioblastoma drug study design - Investing.com India

Dec 31, 2024
pulisher
Dec 31, 2024

Kazia's Brain Cancer Drug Paxalisib Shows 3.8-Month Survival Benefit, FDA Guides Phase 3 Path Forward - StockTitan

Dec 31, 2024
pulisher
Dec 11, 2024

Kazia's Paxalisib Shows Promise in Breast Cancer Trial: Key Data Released at SABCS - StockTitan

Dec 11, 2024
pulisher
Nov 04, 2024

Kazia sets FDA meeting for glioblastoma drug pathway - Investing.com India

Nov 04, 2024
pulisher
Nov 04, 2024

Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme - StockTitan

Nov 04, 2024
pulisher
Oct 30, 2024

U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.65% - MSN

Oct 30, 2024
pulisher
Oct 29, 2024

Leptomeningeal Metastases Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Y-mAbs Therapeutics, Plus Therapeutics, AngioChem, AstraZeneca - The Globe and Mail

Oct 29, 2024
pulisher
Oct 29, 2024

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.65% - MSN

Oct 29, 2024
pulisher
Oct 28, 2024

Upcoming Stock Splits This Week (October 28 to November 1) – Stay Invested - Nasdaq

Oct 28, 2024
pulisher
Oct 16, 2024

Kazia Therapeutics Adjusts ADS Ratio to Boost Nasdaq Listing - Yahoo Finance

Oct 16, 2024
pulisher
Oct 11, 2024

B2i Digital Acting as Marketing Partner for Maxim Group's 2024 Healthcare Virtual Summit - Benzinga

Oct 11, 2024
pulisher
Oct 02, 2024

Paxalisib shows promise in brain metastasis treatment - Investing.com

Oct 02, 2024
pulisher
Oct 02, 2024

Market Recap: Kazia Therapeutics Limited ADR (KZIA)’s Positive Momentum, Closing at 0.43 - The Dwinnex

Oct 02, 2024
pulisher
Oct 02, 2024

Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American - StockTitan

Oct 02, 2024
pulisher
Oct 01, 2024

Kazia Therapeutics Limited ADR (KZIA) Stock: Uncovering a 52-Week Range and Trading Volume - The InvestChronicle

Oct 01, 2024
pulisher
Sep 23, 2024

KZIAKazia Therapeutics Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan

Sep 23, 2024
pulisher
Sep 19, 2024

Immunotherapy Clinical TrialsA New Approach to Treating Cancer - StockTitan

Sep 19, 2024
pulisher
Sep 17, 2024

Take off with Kazia Therapeutics Limited ADR (KZIA): Get ready for trading - SETE News

Sep 17, 2024
pulisher
Sep 12, 2024

KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFER - MarketScreener

Sep 12, 2024
pulisher
Jul 31, 2024

7 Top Stocks Under $10: July 2024 Edition - InvestorPlace

Jul 31, 2024
pulisher
Jul 16, 2024

United States shares higher at close of trade; Dow Jones Industrial Average up 0.53% - Investing.com India

Jul 16, 2024
pulisher
Jul 13, 2024

United States shares higher at close of trade; Dow Jones Industrial Average up 0.62% - Investing.com India

Jul 13, 2024
$20.04
price up icon 2.51%
$72.65
price up icon 3.49%
$32.60
price up icon 1.27%
$24.61
price up icon 6.77%
$98.76
price up icon 0.52%
biotechnology ONC
$230.98
price up icon 1.24%
Kapitalisierung:     |  Volumen (24h):